Key Takeaways
- • California Governor Gavin Newsom signed AB 1415 and SB 351 into law, establishing the most expansive regulatory framework for private equity and hedge fund activity in healthcare at the state level, effective January 1, 2026.
- • AB 1415 requires a 90-day pre-transaction notice to the California Office of Health Care Affordability (OHCA) for material healthcare deals, including asset sales, transfers, leases, and changes of control or governance of healthcare entities and management services organizations (MSOs).
- • SB 351 codifies California's corporate practice of medicine prohibition, explicitly restricting private equity groups and hedge funds from influencing physicians' clinical decisions and medical judgment.
- • The legislation creates mandatory compliance obligations for healthcare providers and private investors operating in California, with noticing entities required to file disclosures covering transactions involving MSOs, healthcare entities, and affiliated ownership structures.
- • These laws significantly expand OHCA's regulatory jurisdiction to transactions previously outside state oversight, potentially impacting deal velocity and transaction structure for PE and hedge fund healthcare investments in the nation's largest state.
Summary
California has enacted two landmark pieces of legislation targeting private equity and hedge fund participation in healthcare, with Governor Gavin Newsom signing AB 1415 and SB 351 into law. Effective January 1, 2026, these bills establish California as a leader in state-level healthcare transaction oversight and represent a substantive shift in regulatory scrutiny over institutional investment activity in the sector.
AB 1415 creates a mandatory pre-transaction notification framework that significantly expands the enforcement powers of the California Office of Health Care Affordability (OHCA). Beginning in 2026, the law requires "noticing entities" to submit written notice to OHCA at least 90 days before entering into material transactions with healthcare entities, MSOs, or entities that own healthcare operations. Material transactions are broadly defined to include the sale, transfer, lease, exchange, option, encumbrance, conveyance, or other disposition of a material amount of assets, as well as any change of control, responsibility, or governance of healthcare entity or MSO assets or operations. This advance notice requirement provides state regulators with an extended review period to assess proposed transactions and potentially challenge deals on affordability, quality, or access grounds before they close.
SB 351 complements AB 1415 by codifying California's longstanding prohibition on the corporate practice of medicine, explicitly barring private equity groups and hedge funds from exercising control over or influencing physicians' clinical decisions and medical judgment. This provision directly constrains the operational control models that PE firms have traditionally deployed in healthcare acquisitions, limiting the ability of financial sponsors to drive clinical protocol changes or physician compensation structures that might conflict with independent medical judgment.
Together, these laws create substantial compliance obligations for healthcare providers and private investors. Industry participants must review existing agreements with MSOs and healthcare entities to ensure alignment with the new restrictions, monitor OHCA regulatory guidance as it develops, and redesign transaction structures to accommodate the 90-day notice period and potential regulatory intervention. The expansion of OHCA's jurisdiction to cover private equity and hedge fund transactions—previously outside the agency's oversight scope—marks a material shift in the regulatory landscape for healthcare investing in California.
AB 1415 creates a mandatory pre-transaction notification framework that significantly expands the enforcement powers of the California Office of Health Care Affordability (OHCA). Beginning in 2026, the law requires "noticing entities" to submit written notice to OHCA at least 90 days before entering into material transactions with healthcare entities, MSOs, or entities that own healthcare operations. Material transactions are broadly defined to include the sale, transfer, lease, exchange, option, encumbrance, conveyance, or other disposition of a material amount of assets, as well as any change of control, responsibility, or governance of healthcare entity or MSO assets or operations. This advance notice requirement provides state regulators with an extended review period to assess proposed transactions and potentially challenge deals on affordability, quality, or access grounds before they close.
SB 351 complements AB 1415 by codifying California's longstanding prohibition on the corporate practice of medicine, explicitly barring private equity groups and hedge funds from exercising control over or influencing physicians' clinical decisions and medical judgment. This provision directly constrains the operational control models that PE firms have traditionally deployed in healthcare acquisitions, limiting the ability of financial sponsors to drive clinical protocol changes or physician compensation structures that might conflict with independent medical judgment.
Together, these laws create substantial compliance obligations for healthcare providers and private investors. Industry participants must review existing agreements with MSOs and healthcare entities to ensure alignment with the new restrictions, monitor OHCA regulatory guidance as it develops, and redesign transaction structures to accommodate the 90-day notice period and potential regulatory intervention. The expansion of OHCA's jurisdiction to cover private equity and hedge fund transactions—previously outside the agency's oversight scope—marks a material shift in the regulatory landscape for healthcare investing in California.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.